OR WAIT null SECS
Charles River’s off-the-shelf lentiviral vector packaging plasmids are intended for use with cell and gene therapies.
Charles River Laboratories, a pharmaceutical company specializing in cell and gene therapies, announced the launch of its lentiviral vector (LVV) packaging plasmids on June 13, 2023. According to a company press release, the immediate availability of these off-the-shelf plasmids is intended to provide a streamlined solution for challenges associated with plasmid sourcing for cell and gene therapies, including capacity bottlenecks, timeline pressures, and process development optimization.
“We are thrilled to announce this addition to our product offering,” said Kerstin Dolph, corporate senior vice-president, Biologics Solutions, Charles River, in the release. “Our LVV packaging plasmids allow us to further support advanced therapy programs and most importantly, help expedite the delivery of safe, effective therapies to those who need them most."
“Charles River’s LVV packaging plasmids offer researchers and manufacturers a high-quality, reliable tool to support their LVV viral vectors production,” said Andrew Frazer, associate director, Scientific Solutions, Charles River, in the release. “The new plasmids will be a valuable resource to develop new treatments for a wide range of programs in preclinical and clinical development with the continuity of supply for commercial use”
Source: Charles River